Vyriad Expands Clinical Study of Oncolytic Virus Therapy in Bladder Cancer Patients


Deprecated: strlen(): Passing null to parameter #1 ($string) of type string is deprecated in /home/medicircle/public_html/script_newsdetails.php on line 75
▴ Vyriad Expands Clinical Study of Oncolytic Virus Therapy in Bladder Cancer Patients
Vyriad, Inc. announced today the addition of new clinical sites in its ongoing clinical study evaluating an intravesical oncolytic measles virus therapy in bladder cancer patients scheduled for radical cystectomy (bladder removal surgery).

Vyriad, Inc. announced today the addition of new clinical sites in its ongoing clinical study evaluating an intravesical oncolytic measles virus therapy in bladder cancer patients scheduled for radical cystectomy (bladder removal surgery). This clinical trial was developed with the lead principal investigator Dr. Bradley Leibovich, Chair of the Department of Urology at Mayo Clinic, and is now open at three sites: Mayo Clinic in Rochester, MN; Ochsner Health in New Orleans, LA; and University of Miami Sylvester Comprehensive Cancer Center, Miami FL.

Vyriad’s oncolytic measles virus (MV-NIS) is designed to target cancer cells without harming healthy cells. MV-NIS selectively infects and kills cancer cells, releasing tumor antigens and inflammatory cytokines that trigger a robust systemic and tumor-specific immune response. Vyriad received a fast-track Small Business Innovation Research (SBIR) grant from the National Cancer Institute to advance this new treatment for bladder cancer patients with assistance from Minnesota’s SBIR Assistance Program.

“Based on previous clinical experience in other cancer indications, we believe that MV-NIS has the potential to reduce disease recurrence or progression following radical cystectomy,” said Stephen Russell, M.D., Ph.D., Vyriad President, and Chief Executive Officer. “If proven efficacious, we would envision future trials investigating MV-NIS for other bladder cancer patients including non-muscle invasive disease.”

The primary objective of this pilot 16-patient study is to assess the safety and preliminary efficacy of intravesical MV-NIS treatment in patients with relapsed bladder cancer who are undergoing bladder removal and are not eligible or do not want chemotherapy.

About Bladder Cancer
Bladder cancer occurs when abnormal cells in the urinary bladder begin to grow uncontrollably. Urothelial carcinoma, the most common type of bladder cancer, starts in the urothelial cells that line the inside of the bladder. In 2020, approximately 81,000 people in the U.S. will be diagnosed with bladder cancer and 18,000 will die from the disease, according to the American Cancer Society.

About Vyriad, Inc.
Vyriad is a clinical-stage company developing virus-based therapeutics, focusing on proprietary oncolytic virus therapies for the treatment of cancers with significant unmet needs, and now a virus-based assay to support the fight against COVID-19. Founded by scientists at Mayo Clinic and the University of Miami, Vyriad programs viruses to selectively attack cancer cells, thereby igniting antitumor immune responses that can complete the process of tumor destruction and prevent disease recurrence.

Our lead platforms, derived from either vesicular stomatitis virus (VSV) or measles virus, are being evaluated in ongoing Phase 1-2 clinical trials addressing multiple cancer types. Vyriad and Regeneron have a broad strategic agreement for the discovery and development of new oncolytic virus treatments for cancer leveraging Vyriad’s VSV platform and the PD-1 inhibitor Libtayo® (cemiplimab), being jointly developed by Regeneron and Sanofi, as well as its unmatched antibody discovery capabilities. Vyriad is a privately held company based in Rochester, Minnesota.

Tags : #Vyriad #Rochester #OncolyticVirus #OncolyticVirusTherapy #BladderCancer #Patients #ClinicalTrial #ClinicalStudy #DrBradleyLeibovich #OchsnerHealth #NationalCancerInstitute

Related Stories

Loading Please wait...

-Advertisements-




Trending Now

Digital Identity Fraud in Healthcare: What India Must KnowNovember 18, 2026
Wearables in Clinical Care: When Should Doctors Trust the Data?November 18, 2026
Cybersecurity for Medical Startups: What Founders MissNovember 18, 2026
Remote Patient Monitoring: The Next Phase of Virtual CareNovember 18, 2026
Digital Health Wallets: Future of Medical Records in IndiaNovember 17, 2026
How Hospitals Can Prepare for a Transparent Healthcare MarketNovember 17, 2026
Childhood Nutrition: Understanding Micronutrient Gaps Beyond CaloriesNovember 16, 2026
Anaemia in Adolescent Girls: Connecting Prevention, Testing and Nutrition SupportNovember 16, 2026
Health Information Exchanges in India: Are Medical Records Finally Going Portable?November 16, 2026
Hospital Accreditation in 2026: What Is Changing Beyond the Checklist?November 16, 2026
Digital Insurance Platforms and India's Health Coverage FutureNovember 14, 2026
ABDM 2.0: India's Digital Health Ecosystem FutureNovember 14, 2026
Vaccine Cold-Chain Management: Protecting Immunisation Quality From Storage to DeliveryNovember 14, 2026
Foodborne Illness Surveillance: How Public Health Systems Track RisksNovember 14, 2026
Interoperability in Indian Healthcare: Why Patient Data Still StrugglesNovember 13, 2026
Tuberculosis Contact Screening: How Preventive Care Works Around ExposureNovember 13, 2026
COPD Care in India: Linking Diagnosis, Inhaler Education and Follow-UpNovember 13, 2026
Management of ANCA Glomerulonephritis: Induction & Maintenance ProtocolsNovember 12, 2026
Smart Hospital Command Centres Transforming IndiaNovember 12, 2026
Gamma Knife Surgery in India: What You Need to KnowNovember 12, 2026